Categories: Web and IT News

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25


Dallas, Texas–(Newsfile Corp. – June 4, 2025) – Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage biotechnology company based in Bellaire, Texas, pioneering RNA interference (RNAi) therapeutics through its proprietary DNAbilize® platform. This innovative technology employs neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while minimizing toxicity. The Company’s lead candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML). A modified version, BP1001-A, is undergoing Phase 1/1b trials for solid tumors and has shown promise in preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors. Bio-Path is also preparing an Investigational New Drug (IND) application for BP1003, a STAT3 inhibitor aimed at treating pancreatic cancer.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Phase 2 prexigebersen data shows potential for FDA approval in AML treatment.
  • BP1001-A trial shows early signs of efficacy in advanced solid tumors.
  • Advancing pipeline backed by strategic R&D and a robust patent portfolio.

Click image above to view full announcement.


About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254522

 

View more news from Reportable, Inc.

You are receiving this email because you have previously indicated your interest in receiving news for Reportable, Inc.

If you no longer want to receive messages from us, you can click here to unsubscribe.

Anti-Spam Policy | Privacy Policy

 

The post Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 first appeared on PressReleaseCC.

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 first appeared on Web and IT News.

awnewsor

Recent Posts

From CEO to Visionary: How Kurt Mackey Bet Fly.io on AI Agents and Disposable Computers

Kurt Mackey once built Fly.io around two big ideas. Applications should run close to their…

1 hour ago

Nikhil Suresh: Why the AI Industry Must Abandon Its Delusions of General Intelligence

The recent commentary from Nikhil Suresh on the Daring Fireball site captures a growing sense…

1 hour ago

Hugging Face CEO Demands OpenAI Pay Up After Rogue AI Agent Breach

Clem Delangue didn’t waste time. The Hugging Face CEO flew to San Francisco last week.…

1 hour ago

Peter Schiff’s SpaceX Warning: A Harbinger for Tech Valuations and Crypto

Peter Schiff rarely pulls punches. The longtime gold advocate and critic of easy money has…

1 hour ago

DeepSeek CEO’s Leaked Four-Hour Rant Rocks China’s AI Ambitions

DeepSeek’s Liang Wenfeng built a reputation as the quiet force behind some of the most…

1 hour ago

Fedora 45 Proposal Brings Browser-Based Remote Installs to Atomic Desktops

Fedora developers have filed a change proposal that could transform how administrators and enthusiasts set…

1 hour ago

This website uses cookies.